Immuneering
IMRX
51 hedge funds and large institutions have $34.3M invested in Immuneering in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 24 reducing their positions, and 8 closing their positions.
2% less funds holding
Funds holding: 52 → 51 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
14.76% less ownership
Funds ownership: 55.3% → 40.54% (-15%)
42% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 24
71% less capital invested
Capital invested by funds: $119M → $34.3M (-$84.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$728K |
| 2 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$453K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$420K |
| 4 |
SM
Southport Management
Wilson,
Wyoming
|
+$364K |
| 5 |
Millennium Management
New York
|
+$290K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.09M |
| 3 |
BlackRock
New York
|
-$4.04M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.44M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.1M |
IMRX Hedge Fund Activity: Q1 2024 in Review
51 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q1 2024, worth a combined $34.3M — down 71% from $119M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of IMRX and 7 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 14 added.
The largest buyer was Vanguard Group, adding an estimated $728K. The largest seller was T. Rowe Price Associates, cutting an estimated $13.8M.
- 51 institutional investors held Immuneering (IMRX) as of Q1 2024, down from 52 in Q4 2023.
- Funds reported $34.3M of Immuneering stock for Q1 2024, down 71% quarter-over-quarter.
- 7 funds opened new Immuneering positions in Q1 2024 and 8 closed out, a net change of -1 holder.
- The largest Immuneering buyer in Q1 2024 was Vanguard Group, an estimated $728K added.
- The largest Immuneering seller in Q1 2024 was T. Rowe Price Associates, an estimated $13.8M sold.
Based on aggregated 13F filings for Q1 2024.